Data gathered: September 16
Alternative Data for Trevi Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 49 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,783 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Trevi Therapeutics
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
| Price | $7.96 |
| Target Price | Sign up |
| Volume | 2,980,000 |
| Market Cap | $1B |
| Year Range | $3.56 - $9.75 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of “Buy” from AnalystsSeptember 14 - ETF Daily News |
|
Siren L.L.C. Sells 42,267 Shares of Trevi Therapeutics, Inc. $TRVISeptember 11 - ETF Daily News |
 |
Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan StanleySeptember 10 - Yahoo |
 |
Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 9 - SeekingAlpha |
|
Raymond James Financial Inc. Has $3.20 Million Stake in Trevi Therapeutics, Inc. $TRVISeptember 8 - ETF Daily News |
|
Wellington Management Group LLP Acquires New Stake in Trevi Therapeutics, Inc. $TRVISeptember 2 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 38,000 | -38,000 | -12M | -14M | -0.090 |
| Q1 '25 | 0 | 37,000 | -37,000 | -10M | -11M | -0.090 |
| Q4 '24 | 150,000 | 0 | 73,000 | -11M | -11M | -0.110 |
| Q3 '24 | 0 | 36,000 | -36,000 | -13M | -13M | -0.130 |
| Q2 '24 | 0 | 38,000 | -38,000 | -12M | -12M | -0.120 |
Insider Transactions View All
| SCIASCIA THOMAS filed to sell 221,373 shares at $6.6. March 26 '25 |
| GOOD JENNIFER L filed to sell 213,313 shares at $6.6. March 25 '25 |
| Simon Farrell filed to sell 76,900 shares at $7.1. March 12 '25 |
| Simon Farrell filed to sell 81,250 shares at $6.7. March 12 '25 |
| GOOD JENNIFER L filed to sell 213,313 shares at $3. September 9 '24 |
Similar companies
Read more about Trevi Therapeutics (TRVI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Trevi Therapeutics ?
The Market Cap of Trevi Therapeutics is $1B.
What is the current stock price of Trevi Therapeutics ?
Currently, the price of one share of Trevi Therapeutics stock is $7.96.
How can I analyze the TRVI stock price chart for investment decisions?
The TRVI stock price chart above provides a comprehensive visual representation of Trevi Therapeutics 's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Trevi Therapeutics shares. Our platform offers an up-to-date TRVI stock price chart, along with technical data analysis and alternative data insights.
Does TRVI offer dividends to its shareholders?
As of our latest update, Trevi Therapeutics (TRVI) does not offer dividends to its shareholders. Investors interested in Trevi Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Trevi Therapeutics ?
Some of the similar stocks of Trevi Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.